Description
CA 19-9 is a tumour marker used to support the monitoring of pancreatic and certain digestive-tract conditions, contributing useful information within a medically guided evaluation.
About the CA 19-9 (Pancreatic/GI) Test
This test measures CA 19-9, a protein that can be raised in cancers of the pancreas and digestive tract, as well as in some benign conditions affecting the bile ducts and liver. It is used mainly for monitoring and follow-up rather than standalone screening. As with all tumour markers, results are interpreted by a doctor alongside imaging and clinical findings.
Preparation and turnaround
A quick venous blood sample is taken with no fasting generally required. Results are usually available within two to three working days. Because CA 19-9 can rise in benign conditions, we recommend reviewing your result with a doctor.
Frequently asked questions
What is CA 19-9 used for?
It supports monitoring of pancreatic and certain digestive-tract conditions, rather than serving as a standalone screening test.
Can it be raised for benign reasons?
Yes. Conditions affecting the bile ducts and liver can raise CA 19-9, so results are interpreted in context by a doctor.
Is fasting required?
No fasting is generally required for the CA 19-9 test.
Reviews
There are no reviews yet.